The Effect of Oral Iron Supplements on Hepcidin, Insulin and Glucose Metabolism in Pregnancy

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Gestational diabetes mellitus (GDM), defined as hyperglycemia with blood glucose values above normal but below those diagnostic of DM, and iron deficiency (ID) with or without anemia (IDA) are common during pregnancy. Both disease patterns are associated with an increased risk of complications during pregnancy and at delivery and may have a variety of negative effects on different aspects of child development. Thus, GDM and ID/IDA during pregnancy should be prevented. Whether iron supplementation with high oral doses acutely increases hepcidin during pregnancy, and whether this acute iron-induced increase in hepcidin decreases insulin sensitivity, is uncertain.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: f
View:

• week of pregnancy 24-28

• pre-pregnancy BMI \<27.5kg/m2

• singleton pregnancy

• Hb \> 8.0 g/dl

⁃ Willing to either:

• not take any iron supplements for 14 days (however, participants will receive a similar amount of total iron during the 4 study days that they would normally receive over 14 days) OR

• to take the multivitamin Burgerstein Schwangerschaft and Stillzeit supplements over the 14 days (contains 30 mg iron)

Locations
Other Locations
Switzerland
Human Nutrition Laboratory ETH Zurich
RECRUITING
Zurich
Contact Information
Primary
Nicole U Stoffel, PhD
nicole.stoffel@hest.ethz.ch
+41 44 632 83 93
Time Frame
Start Date: 2019-07-03
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 30
Treatments
Active_comparator: High Iron Group
15 women taking 100 mg iron twice daily for 4 days (800 mg).
Active_comparator: Low Iron Group
15 women taking 30 mg iron once daily for 14 days (420 mg).
Sponsors
Leads: Swiss Federal Institute of Technology
Collaborators: University Hospital, Zürich

This content was sourced from clinicaltrials.gov